Atea Pharmaceuticals, Inc.
AVIR
$5.27
-$0.41-7.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 155.12M | 159.32M | 146.53M | 120.09M | 102.15M |
| Gross Profit | -155.12M | -159.32M | -146.53M | -120.09M | -102.15M |
| SG&A Expenses | 28.16M | 30.28M | 32.86M | 39.10M | 42.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 183.27M | 189.60M | 179.40M | 159.19M | 145.07M |
| Operating Income | -183.27M | -189.60M | -179.40M | -159.19M | -145.07M |
| Income Before Tax | -171.79M | -175.83M | -164.51M | -146.19M | -135.27M |
| Income Tax Expenses | -6.50M | -6.32M | -6.16M | 831.00K | 861.00K |
| Earnings from Continuing Operations | -165.29 | -169.52 | -158.35 | -147.03 | -136.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.29M | -169.52M | -158.35M | -147.03M | -136.13M |
| EBIT | -183.27M | -189.60M | -179.40M | -159.19M | -145.07M |
| EBITDA | -182.86M | -189.18M | -178.98M | -158.77M | -144.66M |
| EPS Basic | -2.09 | -2.12 | -1.95 | -1.78 | -1.61 |
| Normalized Basic EPS | -1.36 | -1.38 | -1.26 | -1.06 | -0.92 |
| EPS Diluted | -2.09 | -2.12 | -1.95 | -1.78 | -1.61 |
| Normalized Diluted EPS | -1.36 | -1.38 | -1.26 | -1.06 | -0.92 |
| Average Basic Shares Outstanding | 316.43M | 320.12M | 326.09M | 332.42M | 337.79M |
| Average Diluted Shares Outstanding | 316.43M | 320.12M | 326.09M | 332.42M | 337.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |